

## Collaboration with BioVersys AG

Wädenswil, 1st May, 2016 - The group of Cell Physiology & Cellular Engineering and Bioversys AG entered into an agreement for the development of a new cell line to improve the drug discovery process of Bioversys AG

About Bioversys AG: BioVersys AG is a privately-held biopharmaceutical company headquartered in Switzerland. We are committed to delivering long term value to patients and investors by developing new therapies to combat antimicrobial drug resistance, a major unmet medical need.